ALISO VIEJO, Calif., Nov. 29, 2016 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. today announced that Richard Malamut, MD, has joined the company as senior vice president, research and development, and chief medical officer.
Dr. Malamut will lead a seasoned and experienced team working to expand Avanir from a company with two FDA-approved products - NUEDEXTA® and ONZETRA Xsail® - to a leading CNS company with therapies in several neurological conditions with few, if any treatment options. The company is currently investigating treatments in the areas of agitation in Alzheimer's disease, schizophrenia and other neurological conditions. In this capacity, Dr. Malamut will be responsible for the successful development of Avanir's pipeline and will be accountable for leading interactions and negotiations with the FDA and other global regulatory agencies. He will also have strategic and operational responsibilities for the company's research and development function. "Richard will play an important role at Avanir as we continue our commitment to develop innovative treatments to address the unmet medical needs of people with CNS disorder s," said Rohan Palekar, president and CEO of Avanir. "His background in all stages of product development, from conducting feasibility studies to serving as moderator for FDA Advisory Committee meetings, as well as his expertise in neurology, will be invaluable as we continue our focus on R&D and building our pipeline." "I am honored to have the opportunity to lead this talented R&D team," said Dr. Malamut. "Avanir's pipeline is focused on addressing difficult CNS disorders that need new treatment solutions, and I am excited to play a role in this important mission."